SA520411881B1 - صياغات إطلاق مديد لتطبيقات داخل المفصل - Google Patents

صياغات إطلاق مديد لتطبيقات داخل المفصل

Info

Publication number
SA520411881B1
SA520411881B1 SA520411881A SA520411881A SA520411881B1 SA 520411881 B1 SA520411881 B1 SA 520411881B1 SA 520411881 A SA520411881 A SA 520411881A SA 520411881 A SA520411881 A SA 520411881A SA 520411881 B1 SA520411881 B1 SA 520411881B1
Authority
SA
Saudi Arabia
Prior art keywords
intra
extended release
release formulations
oxabicyclo
dichlorophenyl
Prior art date
Application number
SA520411881A
Other languages
Arabic (ar)
English (en)
Inventor
فيش أندرياس
أولريك ريبسيل بيرند
كاستانولي كارلو
لورشيدر ماثيلد
لاكسمان نيهاركار مانجالي
Original Assignee
نوفارتيس إيه جي
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by نوفارتيس إيه جي filed Critical نوفارتيس إيه جي
Publication of SA520411881B1 publication Critical patent/SA520411881B1/ar

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4465Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SA520411881A 2017-11-10 2020-04-30 صياغات إطلاق مديد لتطبيقات داخل المفصل SA520411881B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762584589P 2017-11-10 2017-11-10
US201862743864P 2018-10-10 2018-10-10

Publications (1)

Publication Number Publication Date
SA520411881B1 true SA520411881B1 (ar) 2024-01-04

Family

ID=64402238

Family Applications (1)

Application Number Title Priority Date Filing Date
SA520411881A SA520411881B1 (ar) 2017-11-10 2020-04-30 صياغات إطلاق مديد لتطبيقات داخل المفصل

Country Status (23)

Country Link
US (1) US20210177824A1 (enExample)
EP (1) EP3706710B1 (enExample)
JP (1) JP7284750B2 (enExample)
KR (1) KR20200087138A (enExample)
CN (1) CN111278410A (enExample)
AU (1) AU2018364685B2 (enExample)
CA (1) CA3075722A1 (enExample)
CL (1) CL2020001156A1 (enExample)
DK (1) DK3706710T3 (enExample)
ES (1) ES2981903T3 (enExample)
FI (1) FI3706710T3 (enExample)
HR (1) HRP20240808T1 (enExample)
HU (1) HUE066971T2 (enExample)
IL (2) IL305541A (enExample)
LT (1) LT3706710T (enExample)
MX (2) MX2020004477A (enExample)
PL (1) PL3706710T3 (enExample)
PT (1) PT3706710T (enExample)
RS (1) RS65659B1 (enExample)
SA (1) SA520411881B1 (enExample)
SI (1) SI3706710T1 (enExample)
TW (2) TW202400164A (enExample)
WO (1) WO2019092637A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113015735B (zh) 2018-12-06 2024-06-21 诺华股份有限公司 用于诱导软骨发生以治疗关节损害的5-羟基-7-氧杂双环[2.2.1]庚烷-2-甲酰胺衍生物
KR20220076371A (ko) * 2020-11-30 2022-06-08 주식회사 엘지화학 캐스파제 저해제를 함유하는 주사용 조성물 및 이의 제조 방법
KR20240133027A (ko) 2023-02-28 2024-09-04 주식회사 포스테라헬스사이언스 올리고펩타이드를 포함하는 서방형 입자 및 이의 제조 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Fgf-18之凍乾調配物
PE20161432A1 (es) * 2014-05-13 2017-01-08 Novartis Ag Compuestos y composiciones para inducir condrogenesis

Also Published As

Publication number Publication date
EP3706710B1 (en) 2024-04-10
TW201922245A (zh) 2019-06-16
KR20200087138A (ko) 2020-07-20
MX2023007036A (es) 2023-06-28
IL274149A (en) 2020-06-30
PT3706710T (pt) 2024-06-27
HRP20240808T1 (hr) 2024-09-27
WO2019092637A1 (en) 2019-05-16
JP2021502337A (ja) 2021-01-28
MX2020004477A (es) 2020-08-03
IL274149B1 (en) 2023-10-01
CN111278410A (zh) 2020-06-12
BR112020008806A2 (pt) 2020-10-20
ES2981903T3 (es) 2024-10-14
AU2018364685B2 (en) 2021-05-20
TWI813597B (zh) 2023-09-01
FI3706710T3 (fi) 2024-07-08
TW202400164A (zh) 2024-01-01
IL305541A (en) 2023-10-01
CL2020001156A1 (es) 2020-10-30
CA3075722A1 (en) 2019-05-16
JP7284750B2 (ja) 2023-05-31
PL3706710T3 (pl) 2024-08-05
RS65659B1 (sr) 2024-07-31
DK3706710T3 (da) 2024-07-08
LT3706710T (lt) 2024-07-10
RU2020115439A (ru) 2021-12-10
US20210177824A1 (en) 2021-06-17
IL274149B2 (en) 2024-02-01
SI3706710T1 (sl) 2024-08-30
RU2020115439A3 (enExample) 2021-12-10
HUE066971T2 (hu) 2024-09-28
EP3706710A1 (en) 2020-09-16
AU2018364685A1 (en) 2020-03-26

Similar Documents

Publication Publication Date Title
EP4491199A3 (en) Gadolinium bearing pcta-based contrast agents
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
PH12018501956A1 (en) 3-desoxy derivative and pharmaceutical compositions thereof
EP4420679A3 (en) Lipids and lipid nanoparticle formulations for delivery of nucleic acids
HK1231471A1 (zh) 6-杂芳氧基-和6芳氧基-喹啉-2-甲酰胺及其用途
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
MX418519B (es) Inhibidores selectivos de jak1
AU2016343803A8 (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
MX2024013464A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos
MX2023007036A (es) Formulaciones de liberacion prolongada para aplicaciones intra-articulares.
EA201891267A1 (ru) Фармацевтическая композиция, содержащая действенный ингибитор urat1
MX2020012978A (es) Sales de sepiapterina farmacéuticamente aceptables.
PH12020550698A1 (en) 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors
WO2018209363A3 (en) PROPIONIC ACID DERIVATIVES AND ASSOCIATED METHODS OF USE
MX2021002981A (es) Pirrolinas fusionadas que actuan como inhibidores de la proteasa 30 especifica de la ubiquitina (usp30).
EP4327880A3 (en) Solid state form of ribociclib succinate
JOP20180071B1 (ar) استخدام مشتقات أمينو ألكيل بنزوثيازبين
NZ734400A (en) Amide compounds as 5-ht4 receptor agonists
TN2019000204A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
WO2018201167A3 (en) Propionic acid derivatives and methods of use thereof
WO2017177004A8 (en) Tertiary amides and method of use
PH12021552020A1 (en) Pharmaceutical formulations
SG10201806809QA (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
MX2021003232A (es) Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa.
MX2021002878A (es) Inhibidores de cd73 y usos farmaceuticos de los mismos.